President Donald Trump on 23 July promoted his administration's new TrumpRx programme at a rally in Marietta, Georgia, claiming it would deliver the steepest prescription drug price cuts in American history by forcing pharmaceutical companies to match the lowest prices charged in other developed nations. The initiative, built around a 'most favoured nation' pricing policy, directs that the United States must pay no more for any medicine than the cheapest price available among peer countries.

What TrumpRx Promises

At the heart of the programme is a price-parity mechanism: if a drug sells for $10 in London or Munich, American consumers should not pay $100 to $120 for the same pill in New York City, Chicago, or Los Angeles — a disparity Trump described as 'unfair.' The administration has launched an online platform, TrumpRx.gov, where Americans can compare medicine prices and, according to Trump, access rates 'you never believed.'

Trump claimed the policy has already reversed decades of overpricing. 'For decades, Americans paid the highest price for prescription drugs anywhere in the world,' he said at the rally. 'Now we're paying the lowest price anywhere in the world.'

Negotiations With Drug Firms and Foreign Governments

Trump described a two-front negotiation: first with pharmaceutical manufacturers, who he said 'fought' the administration before eventually conceding, and then with foreign governments. He recounted pressing French President Emmanuel Macron to raise the prices France pays for medicines, arguing that low overseas prices have long been cross-subsidised by American consumers.

According to Trump, France initially declined before agreeing after the US threatened tariffs on French wine and champagne. 'And we got France, and we got all of them the same way,' he said. The administration has not independently detailed the terms of any such agreements with foreign governments.

Scale of the Claimed Reduction

Trump asserted the cuts amount to reductions of 400%, 500%, and 600% — framing them as 'the largest prescription drug price cuts in history.' Independent verification of those figures was not available at the time of the rally. Pharmaceutical pricing analysts have historically noted that list-price reductions and net-price reductions after rebates can differ substantially, a distinction the administration did not address publicly.

Political Framing and Midterm Stakes

Trump suggested the healthcare initiative could be a decisive factor in upcoming midterm elections, telling supporters, 'That alone should win us the midterms.' He urged the crowd to 'make it too big to rig,' signalling the administration intends to campaign actively on the drug-pricing record.

Prescription drug costs have been among the most politically charged domestic issues in the United States for years, with successive administrations — from both parties — promising reform. The Trump administration argues that American consumers have effectively subsidised cheaper medicine prices in Europe and elsewhere for decades, and that the new policy corrects that imbalance. How durably the pricing changes hold — and whether pharmaceutical companies will absorb costs or pass them through in other ways — is likely to shape the programme's legacy.